In today’s increasingly collaborative healthcare ecosystem, effective partnerships and meaningful program support are more than operational niceties—they’re strategic imperatives. Archo.io’s 2024–2025 industry review pulls back the curtain on which companies are leading the way, how stakeholders perceive their contributions, and where unmet needs present future growth opportunities.
Table of Contents
What Defines Partnership Excellence
Archo.io surveyed a wide range of healthcare stakeholders to identify the top companies they’ve partnered with over the past 12–18 months. The methodology focused on:
- Recognition Score: Frequency of mentions by participants.
- Average Rating: Measured on a 7-point scale where 4 represents the industry standard.
- Weighted Score: A composite metric factoring in recognition and quality.
The results revealed both brand strength and depth of impact in areas such as disease education, advisory boards, and patient support.
Leading the Field: Top 10 Companies in Program Partnership
| Rank | Company | Avg. Rating | Recognition Score | Weighted Score |
|---|---|---|---|---|
|
1 |
Janssen |
5.36 |
22.14% |
1.1867 |
|
2 |
Pfizer/Seagen |
5.26 |
22.14% |
1.1646 |
|
3 |
Sanofi/Genzyme |
5.61 |
13.74% |
0.7708 |
|
4 |
Novartis |
5.14 |
14.50% |
0.7445 |
|
5 |
Merck |
5.52 |
11.45% |
0.6323 |
|
6 |
AstraZeneca |
5.45 |
10.69% |
0.5833 |
|
7 |
GSK |
5.46 |
9.16% |
0.5 |
|
8 |
Bayer |
5.48 |
8.40% |
0.4653 |
|
9 |
Abbvie |
5.03 |
6.87% |
0.3456 |
|
10 |
Takeda |
4.82 |
6.11% |
0.2945 |
Category Highlights: What They Excelled In
Janssen dominated the rankings with exceptional scores in:
- Conferences & Symposia: 6.00
- Disease Education & Awareness: 5.96
Pfizer/Seagen saw major strength in:
- Patient Support Programs
- Advisory Boards
Sanofi/Genzyme rose sharply due to:
- Improved stakeholder engagement
- Emphasis on coalitions and public health literacy
Where the Gaps Are: A Roadmap for Industry Growth
Archo.io identified several critical need-gap areas—categories with high stakeholder interest but low actual support from companies:
| Partnership Type | Interest (Avg.) | Support (Avg.) | Gap |
|---|---|---|---|
|
Coalition Support |
5.86 |
4.36 |
-1.50 |
|
Research/Outcomes Assistance |
4.82 |
3.40 |
-1.42 |
|
Evidence-Based Guidelines |
5.30 |
4.00 |
-1.30 |
These present opportunities for companies to expand support and better align with expectations.
Strategic Takeaways: What's Changed & What's Next
- Year-over-Year Trends show consistent performance by top brands but reveal rising competition in advisory-focused domains.
- Stakeholder Expectations are shifting toward more inclusive collaboration—especially in research, evidence generation, and patient advocacy.
Integrated Oncology Networks are gaining prominence, as seen with Pfizer/Seagen’s surge.
Final Thoughts
As healthcare moves beyond transactional engagements, the new frontier is transformational partnerships—those that influence clinical outcomes, drive innovation, and elevate patient experiences. Companies that embrace these principles not only win recognition but shape the future of global health collaboration.
Archo.io’s review sets the bar for what excellence looks like. The question is: who’s ready to meet—and exceed—it?